DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium

Information source: Seoul National University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Observation of Neuromuscular Block

Intervention: Injection of neostigmine (Drug)

Phase: N/A

Status: Completed

Sponsored by: Seoul National University Hospital

Official(s) and/or principal investigator(s):
Ah Young Oh, Principal Investigator, Affiliation: Professor


This study aims to find appropriate dose of neostigmine which is possible to reverse rocuronium or cisatracurium till train of four (TOF) 0. 9 within 10 minutes.

Clinical Details

Official title: Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: time to reverse from light muscle relaxation

Secondary outcome: time to reverse from TOF ratio 0.5 to 0.9


Minimum age: 19 Years. Maximum age: 69 Years. Gender(s): Both.


Inclusion Criteria:

- American Society of Anesthesiologist Physical status classification 1 or 2 elective

surgery under general anesthesia Exclusion Criteria:

- BMI >25 or < 20 kg/m2

- Patients taking intercurrent medication

- Glutamic Oxalacetate Transaminase or Glutamic Pyruvate Transaminase > 40 IU/L, Cr >

1. 4 mg/dl

Locations and Contacts

Eunsu Choi, Seongnam-si, Gyeonggi-do 463-707, Korea, Republic of
Additional Information

Starting date: June 2013
Last updated: June 12, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017